Great Point Partners’s United Therapeutics UTHR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q4
Sell
-86,667
Closed -$16M 49
2021
Q3
$16M Sell
86,667
-89,739
-51% -$17.7M 3.72% 8
2021
Q2
$31.6M Buy
176,406
+20,000
+13% +$3.81M 6.64% 4
2021
Q1
$26.2M Buy
156,406
+6,406
+4% +$1.07M 5.41% 7
2020
Q4
$22.8M Sell
150,000
-490,773
-77% -$64.4M 3.7% 13
2020
Q3
$64.7M Buy
640,773
+20,773
+3% +$2.28M 5.82% 6
2020
Q2
$75M Buy
620,000
+63,748
+11% +$7.17M 6% 7
2020
Q1
$52.7M Buy
556,252
+15,073
+3% +$1.43M 5.51% 6
2019
Q4
$47.7M Buy
541,179
+71,179
+15% +$6.26M 4.15% 12
2019
Q3
$37.5M Buy
+470,000
New +$37.9M 3.44% 13
2019
Q2
Sell
-379,832
Closed -$44.6M 42
2019
Q1
$44.6M Buy
379,832
+29,032
+8% +$3.38M 4.41% 11
2018
Q4
$38.2M Buy
350,800
+50,800
+17% +$5.89M 4.83% 8
2018
Q3
$38.4M Buy
300,000
+130,361
+77% +$16.1M 5.98% 5
2018
Q2
$19.2M Buy
+169,639
New +$18.6M 2.66% 17

Other funds holding UTHR

Great Point Partners's UTHR Position: Q4 2021 in Review

Great Point Partners sold out of United Therapeutics (UTHR) in Q4 2021, closing a stake of 86,667 shares — an estimated $16M sold.

Great Point Partners first reported a position in UTHR in Q2 2018 and held it in 13 quarters. The position peaked at $75M in Q2 2020. 416 funds tracked by Wall St. Rank hold UTHR as of Q4 2021.

  • Great Point Partners reported no remaining United Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Great Point Partners sold 86,667 United Therapeutics shares in Q4 2021, an estimated $16M.
  • Great Point Partners first reported a position in United Therapeutics in Q2 2018 and held it in 13 quarters.
  • Great Point Partners's United Therapeutics position peaked at $75M in Q2 2020.
  • 416 funds tracked by Wall St. Rank held United Therapeutics as of Q4 2021.

Based on Great Point Partners's 13F filing for Q4 2021, filed 14 Feb 2022.